The type 2 diabetes drug tirzepatide, sold as Mounjaro by maker Eli Lilly & Co., also appears to provide weight loss benefits, the company has said. Research that is pending full publication showed that type 2 diabetes patients with overweight or obesity who took the drug lost up to 16% of their body weight over a nearly 17-month period, and the company has said it is applying to the FDA for fast-track approval of the medication for chronic weight management.
Full Story: ABC News (5/2)